Beta Blocker News and Research

RSS
Beta-adrenergic receptor blocking agents (beta-blockers) are drugs with multiple actions on the heart. Blockade of beta-1 receptors results in slowing of heart rate, reduction in myocardial contractility, and lowering of systemic blood pressure. In the context of acute myocardial infarction (AMI), which represents a state of reduced oxygen supply to the affected portion of the heart, these effects may be beneficial as they result in reduced myocardial workload and oxygen demand. Furthermore, beta-blockers may reduce the risk of ventricular arrhythmias, which are an important cause of death following AMI.
Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications increases in IHD but levels still suboptimal

Study shows beta blockers may benefit women with ovarian cancer

Study shows beta blockers may benefit women with ovarian cancer

Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

Study indicates major added benefit of propranolol in some children with haemangioma

Study indicates major added benefit of propranolol in some children with haemangioma

Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

Study: Preoperative interventions improve outcomes of patients undergoing CABG surgery

New treatment for Marfan syndrome works as well as beta blockers

New treatment for Marfan syndrome works as well as beta blockers

Investigational treatment shows promise against Marfan syndrome

Investigational treatment shows promise against Marfan syndrome

Studies evaluate traditional management of heart attack patients after discharge from hospital

Studies evaluate traditional management of heart attack patients after discharge from hospital

QT Medical partners with LA BioMed to identify infants at risk of long QT syndrome

QT Medical partners with LA BioMed to identify infants at risk of long QT syndrome

DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

Penn researchers analyze clinical practice guidelines

Penn researchers analyze clinical practice guidelines

Patients who receive medication instruction sheet more likely to obey physician's instructions

Patients who receive medication instruction sheet more likely to obey physician's instructions

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

PARADIGM-HF trial of LCZ696 for chronic heart failure stopped early for benefit

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

Call for greater beta blocker use in COPD

Call for greater beta blocker use in COPD

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.